Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | See "Remarks" | August 03, 2026 | August 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date August 03, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 6,774 |
Last balance in matching sequence
After 2026-08-03 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-08-03 · Exercise / conversion · Acquired 12,827 · Balance 19,601 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Row 2 · 2026-08-03 · Sale · Disposed 12,827 · Balance 6,774 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025. F4: Represents with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.66 to $35.07, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 25,657 |
Reported balance
After 2026-08-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-03 · Exercise / conversion · Disposed 12,827 · Balance 25,657 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6: Restricted share units were granted on August 1, 2024, with 12,827 vested on each of August 1, 2025 and August 1, 2026, 12,827 vesting on August 1, 2027, and 12,830 vesting on August 1, 2028. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.
F4: Represents with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.66 to $35.07, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6: Restricted share units were granted on August 1, 2024, with 12,827 vested on each of August 1, 2025 and August 1, 2026, 12,827 vesting on August 1, 2027, and 12,830 vesting on August 1, 2028.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2026 Filed Aug 5, 2026 20:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 12,827 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-335026 · ownership.xml · derivative · entry 3 Jover Placid · CIK 0002026165 · See "Remarks" 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,657 Underlying: Ordinary Shares · 12,827 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on August 1, 2024, with 12,827 vested on each of August 1, 2025 and August 1, 2026, 12,827 vesting on August 1, 2027, and 12,830 vesting on August 1, 2028. F6 · derivative.expiration_date: Restricted share units were granted on August 1, 2024, with 12,827 vested on each of August 1, 2025 and August 1, 2026, 12,827 vesting on August 1, 2027, and 12,830 vesting on August 1, 2028. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 20:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 12,827 | $34.88 | $447,350.60 |
DisclosureSEC source: 0001193125-26-335026 · ownership.xml · nonDerivative · entry 2 Jover Placid · CIK 0002026165 · See "Remarks" 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,774 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025. F4 · shares: Represents with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.66 to $35.07, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 20:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 12,827 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-335026 · ownership.xml · nonDerivative · entry 1 Jover Placid · CIK 0002026165 · See "Remarks" 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,601 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 14,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-098506 · ownership.xml · derivative · entry 3 Jover Placid · CIK 0002026165 · See "Remarks" 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,453 Underlying: Ordinary Shares · 14,150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 5, 2025, with 14,150 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 14,153 vesting on March 5, 2029. F6 · derivative.expiration_date: Restricted share units were granted on March 5, 2025, with 14,150 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 14,153 vesting on March 5, 2029. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 14,150 | $31.67 | $448,107.86 |
DisclosureSEC source: 0001193125-26-098506 · ownership.xml · nonDerivative · entry 2 Jover Placid · CIK 0002026165 · See "Remarks" 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,774 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025. F4 · shares: Represents with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 to $32.34, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 14,150 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-098506 · ownership.xml · nonDerivative · entry 1 Jover Placid · CIK 0002026165 · See "Remarks" 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:16 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 37,982 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-096569 · ownership.xml · derivative · entry 1 Jover Placid · CIK 0002026165 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,982 Underlying: Ordinary Shares · 37,982 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on March 4, 2026, with 9,495 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 9,497 vesting on March 4, 2030. F2 · derivative.expiration_date: Restricted share units were granted on March 4, 2026, with 9,495 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 9,497 vesting on March 4, 2030. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 20:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 12,827 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-102992 · ownership.xml · derivative · entry 3 Jover Placid · CIK 0002026165 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,484 Underlying: Ordinary Shares · 12,827 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on August 1, 2024, with 12,827 vested on August 1, 2025, 12,827 vesting on each of August 1, 2026 and August 1, 2027, and 12,830 vesting on August 1, 2028. F5 · derivative.expiration_date: Restricted share units were granted on August 1, 2024, with 12,827 vested on August 1, 2025, 12,827 vesting on each of August 1, 2026 and August 1, 2027, and 12,830 vesting on August 1, 2028. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 20:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 6,053 | $15.16 | $91,748.35 |
DisclosureSEC source: 0000950170-25-102992 · ownership.xml · nonDerivative · entry 2 Jover Placid · CIK 0002026165 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,774 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.13 to $15.31, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 20:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 12,827 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-102992 · ownership.xml · nonDerivative · entry 1 Jover Placid · CIK 0002026165 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,827 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 56,603 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-035498 · ownership.xml · derivative · entry 1 Jover Placid · CIK 0002026165 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,603 Underlying: Ordinary Shares · 56,603 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on March 5, 2025, with 14,150 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 14,153 vesting on March 5, 2029. F2 · derivative.expiration_date: Restricted share units were granted on March 5, 2025, with 14,150 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 14,153 vesting on March 5, 2029. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 11:32 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 51,311 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-090326 · ownership.xml · derivative · entry 1 Jover Placid · CIK 0002026165 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,311 Underlying: Ordinary Shares · 51,311 shares Expires not disclosed F1 · derivative.exercise_price: Each performance share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on August 1, 2024, with 12,827 vesting on each of August 1, 2025, August 1, 2026 and August 1, 2027 and 12,830 vesting on August 1, 2028. F2 · derivative.expiration_date: Restricted share units were granted on August 1, 2024, with 12,827 vesting on each of August 1, 2025, August 1, 2026 and August 1, 2027 and 12,830 vesting on August 1, 2028. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.